Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Phase 3 trials show satralizumab significantly improves proptosis, inflammation, and diplopia in thyroid eye disease with a favorable safety profile, marking a new therapeutic option targeting the IL-6 receptor pathway.
Aficamten, a cardiac myosin inhibitor, demonstrated significant improvements in symptoms, diastolic function, and biomarkers in nonobstructive hypertrophic cardiomyopathy across multiple trials, including the pivotal ACACIA-HCM study.
This article explores disease stability as a key treatment target in COPD, analyzing major phase 3 trials that show stability predicts reduced exacerbations and mortality, supporting its use to guide therapy.
Drug-Induced Liver Injury (DILI) remains a pivotal challenge in drug development, with evolving drug modalities and clinical trial designs prompting updated regulatory perspectives from FDA specialists.
This review contrasts early- and late-phase gynecologic oncology trials, underscoring disparities in trial completion, publication, and racial/ethnic minority enrollment, highlighting the need to improve inclusivity and reporting.
A pilot program using former gynecologic oncology trial participants as patient ambassadors improved confidence and perceptions about clinical trials among trial-naïve patients, highlighting a feasible peer-education approach.
This study identifies that 30% of gynecologic cancer clinical trials fail to complete, with insufficient patient accrual as the leading cause, highlighting crucial factors like intervention type, initiation year, and geographic variations t
This review synthesizes evidence linking periodontitis-induced inflammation with clonal hematopoiesis, exploring implications for tumor metastasis, trial methodology, and microbiome-host crosstalk.
This review synthesizes recent phase I trial data on CD7 CAR-T therapies in relapsed/refractory AML, highlighting promising safety, high response rates, challenges with antigen loss relapse, and avenues for future research.
A comprehensive evidence-based synthesis of the REMAP-CAP trial and major international RCTs, demonstrating that ivermectin fails to improve clinical outcomes, survival, or organ support requirements in hospitalized and non-hospitalized COV
A culturally tailored educational intervention significantly improved clinical trial knowledge and self-efficacy among African American and Hispanic women, highlighting the potential of community partnerships to address disparities in gynec
A study reveals significant variability in ALSFRS-R analysis methods across 45 ALS trials, impacting treatment effect estimates and increasing false-positive risks, with implications for clinical decision-making and drug development.
Researchers developed and validated ADAPT-CEC, an artificial intelligence algorithm that can adjudicate cardiovascular events across different trial definitions. A hybrid approach combining AI with selective human review achieved 95.6% accu
This review synthesizes the 54-month results of the ATTRibute-CM open-label extension, demonstrating that early and continuous acoramidis treatment provides sustained reductions in mortality and cardiovascular hospitalizations while maintai
A pooled analysis of 11,269 patients from the INTERACT and ATACH-II trials reveals that 24-hour systolic blood pressure trajectories, rather than just single targets, significantly influence functional outcomes after intracerebral hemorrhag
This systematic review analyzes the profound underrepresentation of African populations in high-impact clinical trials, revealing a stark disparity in cardiovascular and general medical research that limits the global applicability of evide
The Phase 2b PARADIGM trial reveals that PrimeC, a novel oral combination therapy, is safe and significantly slows functional decline and reduces the risk of death or hospitalization in ALS patients over 18 months.
The EMPATICC trial explored heart failure therapy for patients with advanced cancer in palliative care. While it did not meet its primary endpoint for self-care ability due to high mortality, survivors showed improved cardiac biomarkers and
This review evaluates the LIDA trial’s findings that 3 months of romosozumab followed by denosumab is non-inferior to 12 months of romosozumab, offering a cost-effective strategy to mitigate long-term side effects.
A Phase 3 pragmatic trial found that 12 hours of weekly intensive task-specific training added to usual care does not improve motor recovery in recent spinal cord injury patients, suggesting a potential plateau in the benefits of early reha